Stay updated on Pembrolizumab-Bevacizumab in Brain Metastases Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Bevacizumab in Brain Metastases Clinical Trial page.

Latest updates to the Pembrolizumab-Bevacizumab in Brain Metastases Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check21 days agoChange DetectedThe page has been updated to reflect new results and timelines for the study involving Pembrolizumab and Bevacizumab for treating brain metastases, including changes in response rates and safety assessments. Notably, the study is now marked as completed, and several dates related to results reporting have been added.SummaryDifference11%
- Check28 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
- Check35 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.5 to v2.16.8, and now includes information about HHS Vulnerability Disclosure.SummaryDifference0.2%
- Check49 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.8%
- Check57 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Notably, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest has been deleted.SummaryDifference0.9%
Stay in the know with updates to Pembrolizumab-Bevacizumab in Brain Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Bevacizumab in Brain Metastases Clinical Trial page.